CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease

CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease

Abstract Although in vitro studies suggest that neutralization by monoclonal antibodies (mAbs) against SARS CoV2 Omicron sub lineages is reduced, in vivo virological response data are lacking. MONET (EudraCT: 2021–004188-28) was multi-centric phase 4 open-label parallel randomized clinical trial, co...

Full description

Saved in:
Bibliographic Details
Main Authors: Ilaria Mastrorosa, Alessandro Cozzi-Lepri, Giulia Matusali, Francesca Colavita, Simone Lanini, Martina Rueca, Alessandra Oliva, Giulia Berno, Alessandra Vergori, Silvia Rosati, Jessica Paulicelli, Enrico Girardi, Emanuele Nicastri, Fabrizio Maggi, Andrea Antinori, Valentina Mazzotta, the MONET Clinical Trial Group
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
SARS coronavirus
RCT
Monoclonal antibodies
Antiviral agents
CT value
Antibodies response
Online Access:https://doi.org/10.1038/s41598-025-15641-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-15641-1

Similar Items